ImmuneOnco won the "Top 20 Innovation and Entrepreneurship in Pudong New Area in 2020"
On the September 29, 2021, Pudong New Area held commendation event for "2021 Outstanding Economic Contribution Enterprises ". ImmuneOnco Biopharmaceuticals (Shanghai) Co., Ltd. won the Price of Top 20 of "2020 Pudong New Area Innovation and Entrepreneurship Award ". The chief officers of the People's Government of Pudong New Area attended the commendation event and issued certificates to enterprises with outstanding contributions and addressed appreciation to the winner enterprises for their outstanding contributions to Pudong's economic development.
Dr. Tian Wenzhi, the founder and chairman of ImmuneOnco, said: "I am very pleased that ImmuneOnco is recognized and rewarded by the Government of Shanghai Pudong New Area. This honor fully speaks for the company's strong developmental research capabilities and innovative vitality. ImmuneOnco will accelerate the clinical development of our pipeline drugs and actively promote keynote products to make them market available earlier for the benefit of cancer patients all over the world.ImmuneOnco will take the opportunity of winning the 'Top 20 Innovation and Entrepreneurship in Pudong New Area' as a new beginning to build a high-quality product pipeline as well as a high-rank pharmaceutical talent team for the responsibility of research and development of new drugs and continue to pour new vitality and make contributions to the economic development of Pudong. "
Founded in June 2015 at Zhangjiang Hi-Tech Park of China (Shanghai) Pilot Free Trade Zone, ImmuneOnco focuses on development and research of anti-tumor immunotherapy products, including bi-specific antibody-traps (mAb-Traps), novel recombinant proteins, and target-activated NK cell therapy. Our compounds aim to activate patients’ own immune system to exert anti-tumor effects, and ultimately inhibit endless growth of tumor cells and reverse malignant symptoms, so that patients can return gradually to being healthy. Currently, several new anti-tumor products are in clinical development stage. ImmuneOnco is recognized by authorities as one of the ‘Top 50 Start-up Enterprises with the Most Investment Potential in Shanghai’ in 2016, the "Excellent Enterprise" in the 2017 China Innovation and Entrepreneurship Competition, and one of the winners of the "Enterprise Excellence Award" of Shanghai Science and Technology Entrepreneurship in 2017.